8-K: Celularity Secures $10 Million Standby Equity Facility and Forbearance Agreements

Celularity Inc. has entered into a standby equity purchase agreement with YA II PN, Ltd for up to $10 million, along with related forbearance agreements with Resorts World Inc Pte Ltd and C.V. Starr & Co. Inc.

Summary

• Celularity Inc. has secured a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd, allowing them to sell up to $10 million of Class A common stock over 36 months.
• The company received an initial $3.15 million convertible promissory note from Yorkville, with a 5% original issue discount, resulting in $2.99 million in cash.
• The note carries an 8% annual interest rate, increasing to 18% upon default, and matures on March 13, 2025.
• Yorkville can convert the note into common stock at $6.3171 per share, which will be adjusted to the average VWAP prior to the conversion price reset date, with a floor price of $2.4898.
• The agreement includes a 4.99% beneficial ownership blocker for Yorkville and a cap on share issuance at 19.9% of outstanding common stock.
• Celularity also entered into forbearance agreements with Resorts World Inc Pte Ltd (RWI) and C.V. Starr & Co. Inc., agreeing not to exercise remedies on existing loans until the Yorkville note is paid or until March 13, 2025.
• As part of the RWI agreement, Celularity will issue a warrant to acquire 300,000 shares of common stock at an exercise price of $5.895.
• The interest rates on the loans with RWI and Starr will increase by 100 basis points until the Yorkville note is paid.
• Starr's existing warrants will have their exercise price adjusted to $5.895 per share.

Sentiment

Score: 4

Explanation: The document indicates a need for capital and a reliance on potentially dilutive financing, which is not ideal. While the forbearance agreements provide some relief, the high interest rate on the convertible note and the potential for significant dilution are concerning. The sentiment is therefore slightly negative.

Positives

• The standby equity facility provides Celularity with access to capital over the next 36 months.
• The forbearance agreements with RWI and Starr provide Celularity with some breathing room on existing debt obligations.
• The adjustment of warrant exercise prices may be seen as a positive for warrant holders.
• The company has secured additional funding without immediately diluting existing shareholders.

Negatives

• The convertible note has a high interest rate of 18% upon default, which could be a significant burden.
• The potential for significant dilution exists if the full $10 million in shares are issued under the SEPA.
• The conversion price of the note is subject to a reset, which could result in further dilution.
• The company is increasing interest rates on existing loans which will increase expenses.

Risks

• The company's ability to draw down on the equity facility is dependent on the effectiveness of a resale shelf registration statement.
• The company may not receive additional cash proceeds under the SEPA beyond the Initial Advance.
• The conversion of the promissory note could lead to significant dilution of existing shareholders.
• The company is subject to various events of default under the promissory note, which could trigger acceleration of the debt.
• The company is reliant on the share price remaining above the floor price of $2.4898 to avoid further dilution.

Future Outlook

Celularity expects that any proceeds received from sales to Yorkville under the SEPA will be used for working capital and general corporate purposes. The company may not receive additional cash proceeds under the SEPA beyond the Initial Advance.

Industry Context

This announcement reflects a trend of biotech companies seeking alternative financing methods, such as standby equity facilities, to fund operations and development. The forbearance agreements indicate a need to manage existing debt obligations while pursuing new funding opportunities.

Comparison to Industry Standards

• The use of a standby equity purchase agreement is a relatively common financing method for small-cap and development-stage biotech companies, similar to companies like Agenus Inc. and Mustang Bio, Inc.
• The interest rate on the convertible note, while initially 8%, increases to 18% upon default, which is higher than typical bank loans but not uncommon for high-risk financing.
• The 4.99% beneficial ownership blocker is a standard provision in these types of agreements to avoid triggering change of control provisions and to comply with Nasdaq rules, similar to what is seen in agreements of companies like Cassava Sciences, Inc.
• The warrant issuance to RWI is a common incentive for lenders in these types of transactions, similar to what is seen in agreements of companies like Sorrento Therapeutics, Inc.
• The adjustment of exercise prices on existing warrants is a common practice to incentivize warrant holders to exercise their options, similar to what is seen in agreements of companies like Ocugen, Inc.

Stakeholder Impact

• Shareholders may experience dilution if the full $10 million in shares are issued under the SEPA.
• Lenders (RWI and Starr) will receive increased interest payments on their loans.
• Warrant holders of Starr will have their exercise prices adjusted, potentially increasing the value of their warrants.
• Employees may be impacted by the company's financial stability and future growth prospects.

Next Steps

• Celularity needs to file a resale shelf registration statement with the SEC.
• The company needs to maintain the effectiveness of the registration statement.
• Celularity may need to seek shareholder approval for issuances exceeding the Exchange Cap.
• The company needs to monitor its share price to avoid triggering the floor price on the convertible note.

Key Dates

Keywords

standby equity purchase agreement, convertible promissory note, forbearance agreement, common stock, warrant, dilution, interest rate, conversion price, resale registration, debt financing